BRPI0514124A - anticorpos monoclonais humanos contra a il-4 humana - Google Patents

anticorpos monoclonais humanos contra a il-4 humana

Info

Publication number
BRPI0514124A
BRPI0514124A BRPI0514124-9A BRPI0514124A BRPI0514124A BR PI0514124 A BRPI0514124 A BR PI0514124A BR PI0514124 A BRPI0514124 A BR PI0514124A BR PI0514124 A BRPI0514124 A BR PI0514124A
Authority
BR
Brazil
Prior art keywords
human
monoclonal antibodies
human monoclonal
treatment
specific
Prior art date
Application number
BRPI0514124-9A
Other languages
English (en)
Inventor
Jose M Carballido Herrera
Jan E De Vries
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0514124A publication Critical patent/BRPI0514124A/pt
Publication of BRPI0514124B1 publication Critical patent/BRPI0514124B1/pt
Publication of BRPI0514124B8 publication Critical patent/BRPI0514124B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS MONOCLONAIS HUMANOS CONTRA A IL-4 HUMANA. A invenção refere-se a anticorpos os quais são específicos para a interleucina 4 humana e seu uso no tratamento de doenças mediadas por IL-4 e/ou IgE.
BRPI0514124A 2004-08-03 2005-08-02 anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos BRPI0514124B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
PCT/EP2005/008361 WO2006013087A1 (en) 2004-08-03 2005-08-02 Human monoclonal antibodies against human il-4

Publications (3)

Publication Number Publication Date
BRPI0514124A true BRPI0514124A (pt) 2008-05-27
BRPI0514124B1 BRPI0514124B1 (pt) 2017-01-31
BRPI0514124B8 BRPI0514124B8 (pt) 2021-05-25

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514124A BRPI0514124B8 (pt) 2004-08-03 2005-08-02 anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos

Country Status (29)

Country Link
US (2) US7740843B2 (pt)
EP (2) EP2327726A3 (pt)
JP (1) JP4808712B2 (pt)
KR (1) KR101245996B1 (pt)
CN (1) CN101001877B (pt)
AR (1) AR050044A1 (pt)
AU (1) AU2005268932B2 (pt)
BR (1) BRPI0514124B8 (pt)
CA (1) CA2574289C (pt)
CY (1) CY1115524T1 (pt)
DK (1) DK1817343T3 (pt)
EC (1) ECSP077222A (pt)
ES (1) ES2504415T3 (pt)
HK (1) HK1109158A1 (pt)
HR (1) HRP20140888T1 (pt)
IL (1) IL180789A (pt)
MA (1) MA28981B1 (pt)
MX (1) MX2007001342A (pt)
MY (1) MY141851A (pt)
NO (1) NO20070854L (pt)
NZ (1) NZ552637A (pt)
PE (1) PE20060560A1 (pt)
PL (1) PL1817343T3 (pt)
PT (1) PT1817343E (pt)
SG (1) SG155177A1 (pt)
SI (1) SI1817343T1 (pt)
TN (1) TNSN07036A1 (pt)
TW (1) TWI356828B (pt)
WO (1) WO2006013087A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868647A4 (en) * 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
US20200158716A1 (en) * 2017-07-17 2020-05-21 Massachusetts Institute Of Technology Cell atlas of healthy and diseased barrier tissues
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
WO2020180727A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN117327181A (zh) * 2020-06-22 2024-01-02 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0327283B1 (en) 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
ES2121078T3 (es) 1992-02-19 1998-11-16 Schering Corp Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.
DK0671933T3 (da) 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
ATE286510T1 (de) 1993-09-07 2005-01-15 Smithkline Beecham Corp In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
ATE527278T1 (de) 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
PT1817343E (pt) 2014-09-09
CY1115524T1 (el) 2017-01-04
HK1109158A1 (en) 2008-05-30
IL180789A (en) 2017-01-31
BRPI0514124B8 (pt) 2021-05-25
US7740843B2 (en) 2010-06-22
EP2327726A3 (en) 2012-07-11
TWI356828B (en) 2012-01-21
PE20060560A1 (es) 2006-06-27
EP2327726A2 (en) 2011-06-01
SI1817343T1 (sl) 2014-09-30
US20080241160A1 (en) 2008-10-02
JP2008507985A (ja) 2008-03-21
ECSP077222A (es) 2007-03-29
MX2007001342A (es) 2007-04-02
DK1817343T3 (da) 2014-09-15
HRP20140888T1 (hr) 2014-10-24
AU2005268932B2 (en) 2009-06-25
WO2006013087A8 (en) 2007-03-01
PL1817343T3 (pl) 2014-11-28
AR050044A1 (es) 2006-09-20
WO2006013087A1 (en) 2006-02-09
AU2005268932A1 (en) 2006-02-09
SG155177A1 (en) 2009-09-30
ES2504415T3 (es) 2014-10-08
CA2574289A1 (en) 2006-02-09
KR20070047299A (ko) 2007-05-04
TW200617024A (en) 2006-06-01
MY141851A (en) 2010-07-16
MA28981B1 (fr) 2007-11-01
EP1817343A1 (en) 2007-08-15
NO20070854L (no) 2007-04-24
NZ552637A (en) 2010-02-26
US20100254993A1 (en) 2010-10-07
IL180789A0 (en) 2007-06-03
EP1817343B1 (en) 2014-06-25
CN101001877A (zh) 2007-07-18
JP4808712B2 (ja) 2011-11-02
BRPI0514124B1 (pt) 2017-01-31
CA2574289C (en) 2014-09-16
TNSN07036A1 (en) 2008-06-02
KR101245996B1 (ko) 2013-03-20
CN101001877B (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
BRPI0514124A (pt) anticorpos monoclonais humanos contra a il-4 humana
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
EA201000424A1 (ru) Антитела к il-23
BR0313492A (pt) Formulação de anticorpos humanos para tratar distúrbios associados ao tnf-alfa
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
BRPI0411784A (pt) anticorpos contra interleucina -22 e usos para os mesmos
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1115257T1 (el) ΑΠΟΠΤΩΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΙgE ΠΟΥ ΔΕΣΜΕΥΟΝΤΑΙ ΜΕ ΙgE ΔΕΣΜΕΥΜΕΝΗ ΣΕ ΜΕΜΒΡΑΝΗ
EA201100694A1 (ru) Антитело к cd38 человека и его применение
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2007035922A3 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
ATE448232T1 (de) Substituierte heterozyklen
IS7348A (is) N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
WO2005085288A3 (en) Natural igm antibodies and inhibitors thereof
ATE470478T1 (de) An ovarialkrebs beteiligtes protein

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2631 DE 08-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.